Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives $71.83 Consensus Target Price from Brokerages

Apogee Therapeutics, Inc. (NASDAQ:APGE) has earned an average recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $71.83.

A number of research analysts have recently weighed in on APGE shares. Guggenheim raised their price target on Apogee Therapeutics from $44.00 to $91.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Jefferies Financial Group lifted their target price on shares of Apogee Therapeutics from $37.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Stifel Nicolaus increased their price target on shares of Apogee Therapeutics from $46.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Finally, Wedbush restated an “outperform” rating and set a $87.00 price objective (up from $40.00) on shares of Apogee Therapeutics in a research report on Tuesday, March 5th.

Hedge Funds Weigh In On Apogee Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in Apogee Therapeutics in the 3rd quarter valued at about $105,000. Bank of New York Mellon Corp acquired a new position in Apogee Therapeutics during the third quarter worth approximately $1,271,000. Strs Ohio acquired a new position in Apogee Therapeutics during the third quarter worth approximately $87,000. TD Asset Management Inc acquired a new position in shares of Apogee Therapeutics in the 3rd quarter valued at $677,000. Finally, Platinum Investment Management Ltd. acquired a new position in shares of Apogee Therapeutics in the 3rd quarter valued at $6,042,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Apogee Therapeutics Stock Up 0.2 %

NASDAQ:APGE opened at $54.31 on Friday. Apogee Therapeutics has a fifty-two week low of $14.19 and a fifty-two week high of $72.29. The firm’s fifty day simple moving average is $56.48 and its 200-day simple moving average is $36.77.

Apogee Therapeutics (NASDAQ:APGE) last issued its earnings results on Tuesday, March 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. As a group, analysts forecast that Apogee Therapeutics will post -2.67 EPS for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.